
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549**

FORM 11-K

**FOR ANNUAL REPORTS OF EMPLOYEE STOCK PURCHASE, SAVINGS
AND SIMILAR PLANS PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

(Mark One)

☒ **ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended December 31, 2023

OR

☐ **TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

For the transition period from _____ to _____

Commission File Number 1-2189

- A. Full title of the plan and the address of the plan, if different from that of the issuer named below:

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

- B. Name of issuer of the securities held pursuant to the plan and the address of its principal executive office:

ABBOTT LABORATORIES
100 Abbott Park Road
Abbott Park, Illinois 60064-6049

**FINANCIAL STATEMENTS AND
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ABBOTT LABORATORIES STOCK RETIREMENT PLAN
DECEMBER 31, 2023 AND 2022**

C O N T E N T S

	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3
FINANCIAL STATEMENTS	
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6
NOTES TO FINANCIAL STATEMENTS	7
SUPPLEMENTAL SCHEDULE	
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	19

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants
Abbott Laboratories Stock Retirement Plan

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (the “Plan”) as of December 31, 2023 and 2022, the related statement of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2023 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2002.

Chicago, Illinois
June 25, 2024

Abbott Laboratories Stock Retirement Plan
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2023 and 2022
(Dollars in thousands)

	2023	2022
Assets		
Cash	\$ 81	\$ -
Investments, at fair value	14,271,803	13,132,520
Employer contributions receivable	5,524	-
Notes receivable from participants	94,074	89,059
Accrued interest and dividend income	2,994	2,784
Due from brokers	121,715	108,923
Total assets	14,496,191	13,333,286
Liabilities		
Cash overdraft	-	304
Investments sold short, at fair value	116,452	105,823
Accrued investment expenses	301	200
Due to brokers	159	189,038
Total liabilities	116,912	295,365
NET ASSETS AVAILABLE FOR BENEFITS	<u>\$ 14,379,279</u>	<u>\$ 13,037,921</u>

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2023
(Dollars in thousands)

Additions	
Contributions	
Employer	\$ 205,995
Participant	390,099
Rollovers	<u>57,773</u>
Total contributions	653,867
Investment income	
Net appreciation in fair value of investments	1,422,204
Interest and dividends	<u>135,815</u>
Net investment income	1,558,019
Interest income on notes receivable from participants	<u>4,375</u>
Total additions	2,216,261
Deductions	
Benefits paid to participants	874,701
Other expenses	<u>202</u>
Total deductions	<u>874,903</u>
NET INCREASE	1,341,358
Net assets available for benefits	
Beginning of year	<u>13,037,921</u>
End of year	<u><u>\$ 14,379,279</u></u>

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan is intended to constitute a profit-sharing plan under Section 401(a) of the Internal Revenue Code of 1986, as amended (the “IRC”), with a cash or deferred arrangement under IRC Section 401(k), and a portion of the Plan is intended to constitute an employee stock ownership plan that meets the applicable requirements of IRC Sections 409 and 4975(e)(7). The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

In general, United States employees of Abbott Laboratories (“Abbott”) and selected participating subsidiaries and affiliates may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

Alight Solutions serves as the recordkeeper of the Plan. The Northern Trust Company (“Custodian” or “Trustee”) serves as the Plan’s custodian and trustee.

Contributions and Vesting

Contributions to the Plan are paid to the Abbott Laboratories Stock Retirement Trust (“Trust”). The Trust is administered by the Trustee and an investment committee (the “Committee”).

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate contribute from 2% up to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from pretax earnings, after-tax earnings, or both. The Plan also permits Roth 401(k) contributions and has a Roth 401(k) conversion feature. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contributions are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options available under the Plan, except for investment options closed to new contributions.

Employer matching contributions to the Plan are made each payroll period based on the participating employee’s eligible earnings, unless the employee has elected to participate as a Freedom 2 Save Participant as described below. The employer matching contribution for the year ended December 31, 2023 was 5% of the participant’s eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants may enroll in the Freedom 2 Save program in the Plan. A Freedom 2 Save participant who makes qualified student loan repayments of at least 2% of eligible earnings may receive a Freedom 2 Save employer contribution of 5% of eligible earnings shortly after the end of the year. An enrolled Freedom 2 Save participant who makes elective deferrals to the Plan will not receive employer matching contributions each payroll period but instead may receive a true-up employer matching contribution shortly after the end of the year for any payroll period for which the participant makes elective deferrals and does not receive a Freedom 2 Save employer contribution. Freedom 2 Save employer contributions and true-up employer matching contributions are only made on behalf of Freedom 2 Save participants who meet program guidelines, and who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or terminate employment due to death or qualifying disability during such Plan year.

Employer contributions are invested according to the participant's investment elections.

Cash dividends on Abbott common shares are (1) paid in cash to the participants or beneficiaries, (2) paid to the Plan and distributed in cash to participants or beneficiaries no later than 90 days after the close of the Plan year for which paid, or (3) paid to the Plan and credited to the accounts in which shares are held, as elected by each participant or beneficiary in accordance with rules established by the administrator.

On January 1, 2013, Abbott separated into two publicly traded companies - Abbott and AbbVie Inc. ("AbbVie"). The separation of Abbott and AbbVie was a tax-free distribution where Abbott shareholders received one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Participants who received AbbVie stock through this distribution may continue to hold the stock in their Plan accounts but may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan; however, participants may elect to reinvest their AbbVie dividends in AbbVie stock. If no election is made, AbbVie dividends are invested in the Plan's default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other available investment options.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

Service	Vesting percentage
Less than two years	0%
Two years or more	100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65. Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in employer contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee's termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with Abbott within a given period of time, (2) pay Plan expenses as deemed appropriate by the Administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2023, forfeitures reduced Abbott's employer contributions by approximately \$4.0 million. Approximately \$1.0 million and \$938,000 in forfeitures were available at the end of 2023 and 2022, respectively.

Distributions and In-Service Withdrawals

Following retirement, termination or death (or for some participants from merged-in plans, upon disability), participants or their beneficiaries may elect to receive a distribution in installments, in a single lump sum or in a partial lump sum. Participants may elect a direct rollover of their accounts. Also, upon termination, participants may elect to defer distribution to a future date but, after termination of employment, distribution must be made by the 1st of April following the year the participant reaches age 73 or, if earlier, the 31st of December following the year in which the participant dies. Interest, dividends and other earnings will continue to accrue on such deferred amounts.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including Roth rollover accounts and merged-in plan rollover accounts) and, after age 59 $\frac{1}{2}$, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant's account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, subject to certain limitations.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to \$50,000, subject to IRC limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee's anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee's anticipated retirement date, if sooner). Repayment is made through periodic payroll deductions or by sending in payments, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan offers a variety of investment options to participants. Certain investment options are structured as separately managed accounts; therefore, the Plan owns the individual investment holdings within the separately managed accounts and reflects them within the investments of the Plan.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock, mutual funds, REITs and futures contracts - Valued at the published market price per share or unit multiplied by the number of respective shares or units held.

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value ("NAV") provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

Corporate debt, government debt and other - Valued at the published market price or prices obtained from independent financial services industry-recognized vendors multiplied by the number of respective units held. Prices obtained from vendors are on the basis of bid or mid evaluations in accordance to a region's market convention, using factors which include but are not limited to market quotations, yields, maturities, and the bond's terms and conditions. Proprietary methods are used to arrive at the evaluated price, which represent the price a dealer would pay for a security.

Certificate of deposit - Valued at amortized cost, which approximates fair value given the instruments' short duration of less than 130 days.

Futures contracts

One of the investment options structured as a separately managed account uses futures contracts as part of its investment strategy. A futures contract represents a commitment for the future purchase or sale of an asset or index at a specified price on a specified date. Futures contracts are exchange-traded and settle daily. Upon entering into the contracts, the investment manager of the separately managed account is required to deposit, either in cash or securities, an amount equal to a certain percentage of the notional value of the contract. Subsequent payments are then made or received by the Plan, depending on the daily fluctuation in the value of the underlying contracts.

As of December 31, 2023 and 2022, the Plan held futures contracts with a notional amount of approximately \$803,000 and \$1.6 million, respectively. Notional amounts do not quantify risk or represent assets or liabilities of the Plan, but are used in the calculation of the cash settlements under the contracts. The fair value of these derivative contracts was not material at December 31, 2023 and 2022. Changes in fair value are accounted for as investment income (loss) within net appreciation in fair value of investments and totaled approximately \$(125,000) for the year ended December 31, 2023.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

Short sales

One of the investment options structured as a separately managed account utilizes short sales as part of its investment strategy. Short sales are transactions in which the separately managed account sells an investment it does not own in anticipation of a decline in value of that investment. To complete the transaction, the separately managed account must borrow the investment to make delivery to the buyer. The separately managed account is obligated to replace the investment borrowed by purchasing the investment at market price at the time of replacement. The price at such time may be more or less than the price at which the investment was sold by the separately managed account. When an investment is sold short, a decrease in the value of the investment will be recognized as a gain and an increase in the value of the investment will be recognized as a loss.

The following tables summarize the basis used to measure investment assets and liabilities at fair value at December 31, 2023 and 2022 (dollars in thousands):

2023	Basis of Fair Value Measurement				Total
	Quoted Prices in Active Markets	Significant Other Observable Inputs	Significant Unobservable Inputs	Measured at NAV	
Assets - Investments:					
Common stock	\$ 5,071,247	\$ -	\$ -	\$ -	\$ 5,071,247
Mutual funds	112,479	-	-	-	112,479
REITs	25,697	-	-	-	25,697
Collective trust funds	-	-	-	8,074,869	8,074,869
Corporate debt	-	269,066	-	-	269,066
Government debt	-	32,173	-	-	32,173
Private 40-Act mutual funds	-	-	-	676,472	676,472
Other	-	9,800	-	-	9,800
Total investments at fair value	<u>\$ 5,209,423</u>	<u>\$ 311,039</u>	<u>\$ -</u>	<u>\$ 8,751,341</u>	<u>\$ 14,271,803</u>

2023	Basis of Fair Value Measurement				Total
	Quoted Prices in Active Markets	Significant Other Observable Inputs	Significant Unobservable Inputs	Measured at NAV	
Liabilities - Investments sold short:					
Government debt	\$ -	\$ 116,452	\$ -	\$ -	\$ 116,452

Total						
investments						
sold short						
at fair value	\$	-	\$ 116,452	\$	-	\$ 116,452

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

2022	Basis of Fair Value Measurement				Total	
	Quoted Prices in	Significant Other	Significant	Measured at		
	Active Markets	Observable Inputs	Unobservable Inputs	NAV		
Assets - Investments:						
Common stock	\$ 5,310,018	\$ -	\$ -	\$ -	\$ 5,310,018	
Mutual funds	107,725	-	-	-	107,725	
REITs	24,887	-	-	-	24,887	
Collective trust funds	-	-	-	6,706,991	6,706,991	
Corporate debt	-	239,076	-	-	239,076	
Government debt	-	260,737	-	-	260,737	
Private 40-Act mutual fund	-	-	-	477,645	477,645	
Certificate of deposit	-	2,501	-	-	2,501	
Other	-	2,940	-	-	2,940	
Total investments at fair value	\$ 5,442,630	\$ 505,254	\$ -	\$ 7,184,636	\$ 13,132,520	

2022	Basis of Fair Value Measurement				Total
	Quoted Prices in	Significant Other	Significant	Measured at	
	Active Markets	Observable Inputs	Unobservable Inputs	NAV	
Liabilities -					
Investments sold short:					
Government debt	\$ -	\$ 105,823	\$ -	\$ -	\$ 105,823
Total investments sold short at fair value	\$ -	\$ 105,823	\$ -	\$ -	\$ 105,823

Participants are permitted to make redemptions from the Plan's investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2023 and 2022. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if

that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	2023			
	Fair value (NAV)	Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:				
Collective trusts	\$ 8,074,869	Daily	0 - 5 days	--
Funds not filing as direct filing entity:				
Private 40-Act mutual funds				
Asset-backed securities	29,900	Daily	--	Yes (a)
Corporate fixed income	55,771	Daily	--	Yes (a)
Inflation-indexed bonds	8,031	Daily	--	Yes (a)
International fixed income	22,751	Daily	--	Yes (a)
Mortgage-related securities	30,103	Daily	--	Yes (a)
Municipal fixed income	2,573	Daily	--	Yes (a)
Short-term fixed income	486,796	Daily	--	Yes (a)
U.S. Government securities	40,547	Daily	--	Yes (a)
	676,472			
	<u>\$ 8,751,341</u>			
	2022			
	Fair value (NAV)	Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:				
Collective trusts	\$ 6,706,991	Daily	0 - 5 days	--
Funds not filing as direct filing entity:				
Private 40-Act mutual funds				
Short-term fixed income	477,645	Daily	--	Yes (a)
	<u>\$ 7,184,636</u>			

- (a) The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of \$250,000 or 1% of the respective fund's net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on an accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie stock. Investment fees for mutual funds, REITs, collective trusts, and managed accounts are charged against the net assets of the respective fund. Abbott pays other recordkeeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants' common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2023 and 2022 is presented below:

	2023	2022
Abbott common shares, 26,051,349 and 26,635,240 shares, respectively (dollars in thousands)	\$ 2,867,472	\$ 2,924,283
Market value per share	\$ 110.07	\$ 109.79

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Trustee and shares of the Trustee's common stock. A significant portion of the Plan's assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2023, the Plan received \$54 million in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants' account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant's share in the Trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

NOTE F - TAX STATUS

The Internal Revenue Service ("IRS") has determined and informed Abbott by a letter dated April 13, 2022, that the Plan and related Trust are designed in accordance with applicable sections of the IRC. The Plan has been amended since the applicable date of the determination letter. However, the Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable requirements of the IRC.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the IRS or other applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2023 and 2022, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions. There are currently no audits in progress.

Abbott Laboratories Stock Retirement Plan
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2023 through the date these financial statements were issued. Other than described below, management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

As of January 1, 2024, all eligible participants may contribute pre-tax, Roth and after tax contributions up to a total of 50% of eligible earnings (previously capped at 25%), subject to certain limitations.

Effective June 1, 2024, Plan participants who are not actively participating in the Abbott Laboratories Annuity Retirement Plan may receive an annual employer contribution equal to 3% of the participant's eligible earnings, regardless of whether the participant contributes to the Plan. The 3% annual employer contribution will be made shortly after the end of the Plan year only to the eligible participants who either are employed or on a qualifying leave of absence at the end of the applicable Plan year or who have terminated from employment during that Plan year due to death or qualifying retirement or disability during such Plan year. The annual 3% employer contributions will follow the same vesting schedule as the employer matching contributions, becoming fully vested after two years of credited service under the Plan.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
(a)	(b) Identity of issue, borrower, lessor, or similar party			
	Common stock - employer securities			
*	ABBOTT LABORATORIES, common shares			\$ 2,867,472
	Common stock			
	5TH 3RD BANCORP COM			811
	ABBVIE INC.			1,969,750
	ACADIA HEALTHCARE CO INC COM			241
	ACUITY BRANDS INC COM			221
	ADT INC DEL COM			50
	ADVANCE AUTO PTS INC COM			125
	AECOM			420
	AES CORP COM			174
	AFFILIATED MANAGERS GROUP INC COM STK			182
	AFFIRM HLDGS INC CL A CL A			382
	AFLAC INC COM			1,684
	AGCO CORP COM			261
	AGILENT TECHNOLOGIES INC COM			263
	AGILON HEALTH INC COM			13
	AIR LEASE CORP CL A CL A			151
	AKAMAI TECHNOLOGIES INC COM STK			610
	ALASKA AIR GROUP INC COM			169
	ALBEMARLE CORP COM			584
	ALBERTSONS COS INC CL A CL A			304
	ALLEGION PLC COMMON STOCK			30
	ALLIANT ENERGY CORP COM			447
	ALLISON TRANSMISSION HOLDING			163
	ALLSTATE CORP COM			1,271
	ALLY FINL INC COM			328
	ALNYLAM PHARMACEUTICALS INC COM			161
	AMC ENTMT HLDGS INC CL A NEW			42
	AMCOR PLC ORD USD0.01			482
	AMDOCS ORD GBP0.01			356
	AMEDISYS INC COM			105
	AMER FINL GROUP INC OH COM STK			300
	AMEREN CORP COM			654
	AMERICAN AIRLINES INC COM USD1			195
	AMERICAN WTR WKS CO INC NEW COM			889

AMETEK INC NEW COM	1,310
AMPHENOL CORP NEW CL A	993
ANSYS INC COM	190
ANTERO MIDSTREAM CORPORATION	99
ANTERO RES CORP COM	221
APA CORP COM	44
APARTMENT INCOME REIT CORP COM	180
APPLOVIN CORP COM CL A COM CL A	215
APTARGROUP INC COM	278
APTIV PLC COM USD	839
ARAMARK COM	227
ARCH CAPITAL GROUP COM STK	787
ARDAGH METAL PACKAGING SA	2
ARMSTRONG WORLD INDS INC NEW COM STK	106
ARROW ELECTR INC COM	233
ASHLAND INC COM USD0.01	139
ASPEN TECHNOLOGY INC COM USD0.10	209
ASSURANT INC COM	308

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	ASSURED GUARANTY LTD COMMON STK			147
	ATMOS ENERGY CORP COM			592
	AUTONATION INC COM			147
	AVANGRID INC COM			80
	AVANTOR INC COM			533
	AVERY DENNISON CORP COM			378
	AVIS BUDGET GROUP INC COM STK			80
	AVNET INC COM			157
	AXALTA COATING SYSTEMS LTD COM			
	USD1.00			232
	AXIS CAPITAL HOLDINGS LTD COM			149
	AZEK CO INC CL A CL A			175
	AZENTA INC COM USD0.01			133
	BAKER HUGHES CO			1,198
	BALL CORP COM			613
	BANK NEW YORK MELLON CORP COM STK			1,388
	BANK OZK COM			184
	BATH & BODY WORKS INC COM USD0.5 WI			343
	BAXTER INTL INC COM			677
	BENTLEY SYS INC CL B CL B			26
	BERKLEY W R CORP COM			488
	BERRY GLOBAL GROUP INC			278
	BEST BUY INC COM STK			456
	BILL HOLDINGS INC COM USD0.00001			289
	BIO RAD LABORATORIES INC CL A CL A			230
	BIOGEN INC COMMON STOCK			1,289
	BIOMARIN PHARMACEUTICAL INC COM			550
	BIO-TECHNE CORP COM			24
	BIRKENSTOCK HOLDING PLC COM NPV			36
	BJS WHSL CLUB HLDGS INC COM			200
	BLOCK H & R INC COM			87
	BLOCK INC			911
	BLUE OWL CAP INC COM CL A			201
	BOK FINL CORP COM NEW			85
	BORG WARNER INC COM			289
	BOSTON BEER INC CL A CL A			8

BOYD GAMING CORP COM	157
BRIGHT HORIZONS FA COM USD0.001	164
BRIGHTHOUSE FINL INC COM	108
BROADRIDGE FINL SOLUTIONS INC COM STK	138
BROOKFIELD RENEWABLE CORP CLASS A SUBORDINATE VOTING SHARES WI	133
BROWN & BROWN INC COM	355
BROWN FORMAN CORP CL A CL A	19
BROWN-FORMAN INC CL B NON-VTG COM	75
BRUNSWICK CORP COM	214
BUILDERS FIRSTSOURCE INC COM STK	709
BUNGE GLOBAL SA F COMMON STOCK	504
BWX TECHNOLOGIES INC COM	201
C H ROBINSON WORLDWIDE INC COM NEW COM NEW	77
CABLE ONE INC COM	100
CACI INTL INC CL A CL A	246
CAESARS ENTMT INC NEW COM	198
CAMPBELL SOUP CO COM	287
CAPRI HOLDINGS LTD COM NPV	196
CARDINAL HLTH INC	419

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date &	(d) Cost **	(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest		value
	Common stock - continued			
	CARLISLE COMPANIES INC COM			523
	CARLYLE GROUP INC COM			298
	CARMAX INC COM			396
	CARNIVAL CORP COM PAIRED			637
	CARRIER GLOBAL CORPORATION COM USD0.01 WI			1,655
	CARTER INC FORMERLY CARTER HLDGS INC TO 09/13/2003 COM			94
	CASEYS GEN STORES INC COM			302
	CATALENT INC COM			279
	CAVA GROUP INC COM			5
	CBOE GLOBAL MARKETS INC			651
	CBRE GROUP INC CL A CL A			976
	CCC INTELLIGENT SOLUTIONS HLDGS INC COM			79
	CDW CORP COM			62
	CELANESE CORP DEL COM STK			531
	CENTERPOINT ENERGY INC COM			624
	CERTARA INC COM			47
	CF INDS HLDGS INC COM			528
	CHARLES RIV LABORATORIES INTL INC COM			415
	CHEMED CORP NEW COM			84
	CHEMOURS CO COM			163
	CHESAPEAKE ENERGY CORP COM NEW 01/2021			335
	CHURCH & DWIGHT INC COM			83
	CIENA CORP COM NEW			230
	CIN FNCL CORP COM			549
	CINTAS CORP COM			198
	CIRRUS LOGIC INC COM			159
	CITIZENS FINL GROUP INC COM			534
	CLARIVATE PLC			151
	CLEAN HBRS INC COM			305
	CLEARWAY ENERGY INC CL A CL A			28
	CLEARWAY ENERGY INC CL C CL C			79

CLEVELAND CLIFFS USD0.125	351
CMS ENERGY CORP COM	584
CNA FNCL CORP COM	39
CNH INDUSTRIAL NV	412
COGNEX CORP COM	249
COGNIZANT TECH SOLUTIONS CORP CL A	1,327
COHERENT CORP COM	195
COINBASE GLOBAL INC COM CL A	1,019
COLUMBIA BKG SYS INC COM	192
COLUMBIA SPORTSWEAR CO COM	96
COM ALCOA CORPORATION COM USD0.01	210
COMERICA INC COM	255
COMM BANCSHARES INC COM	223
CONAGRA BRANDS INC COM USD5	473
CONCENTRIX CORP	149
CONS EDISON INC COM	1,090
CONSTELLATION ENERGY CORPORATION COM NPV WI	1,299
COOPER	635
CORE & MAIN INC COM CL A COM CL A	187
COREBRIDGE FINL INC COM	171
CORNING INC COM	802
CORTEVA INC COM USD0.01 WI	1,181
COSTAR GROUP INC COM	695

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	COTERRA ENERGY INC COM			658
	COTY INC COM CL A COM CL A			162
	CRANE CO NEW COM			196
	CRANE NXT CO COM USD1.00			95
	CREDIT ACCEP CORP MICH COM			117
	CROWN HLDGS INC COM			338
	CULLEN / FROST BANKERS INC COM			223
	CUMMINS INC			1,175
	CURTISS WRIGHT CORP COM			292
	D R HORTON INC COM			1,634
	DARDEN RESTAURANTS INC COM			365
	DARLING INGREDIENTS INC COMSTK			273
	DAYFORCE INC			313
	DELTA AIR LINES INC DEL COM NEW COM NEW			849
	DENTSPLY SIRONA INC COM			261
	DEVON ENERGY CORP NEW COM			1,005
	DIAMONDBACK ENERGY INC COM			956
	DICKS SPORTING GOODS INC OC-COM OC-COM			283
	DISCOVER FINL SVCS COM STK			970
	DOLBY LABORATORIES INC CL A COM STK			177
	DOLLAR TREE INC COM STK			1,024
	DONALDSON INC COM			160
	DOORDASH INC CL A COM USD0.00001 CLASS A			226
	DOVER CORP COM USD1.00			743
	DOXIMITY INC COM USD0.001 CL A			65
	DRIVEN BRANDS HLDGS INC COM			31
	DROPBOX INC CL A CL A			30
	DT MIDSTREAM INC COM USD0.01 WI			184
	DTE ENERGY CO COM			787
	DUN & BRADSTREET HLDGS INC COM			112
	DUPONT DE NEMOURS INC COMMON STOCK			1,222
	DXC TECHNOLOGY CO COM			162

EAGLE MATLS INC COM	82
EAST WEST BANCORP INC COM	349
EASTMAN CHEM CO COM	370
EBAY INC COM USD0.001	756
ECHOSTAR	49
EDISON INTL COM	935
ELANCO ANIMAL HEALTH INC COM	252
ELECTR ARTS COM	1,281
ELEMENT SOLUTION INC COM	179
EMCOR GROUP INC COM	225
ENCOMPASS HEALTH CORP COM USD0.01	213
ENOVIS CORPORATION COM USD0.001	102
ENTEGRIS INC COM	587
ENTERGY CORP NEW COM	742
ENVISTA HLDGS CORP COM	136
EQT CORP COM	481
EQUIFAX INC COM	322
ESAB CORPORATION COM USD0.001 WI	168
ESSENTIAL UTILS INC COM	312
ETSY INC COM	151
EURONET WORLDWIDE INC COM	83
EVERCORE INC	210

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	EVEREST GROUP LTD			452
	EVERGY INC COM NPV			403
	EVERSOURCE ENERGY COM			745
	EXACT SCIENCES CORP COM			298
	EXELIXIS INC COM STK			68
	EXPEDIA GROUP INC COM USD0.001			193
	EXPEDITORS INTL WASH INC COM			561
	F N B CORP PA COM			172
	F5 INC COM STK NPV			365
	FASTENAL CO COM			321
	FERGUSON PLC ORD GBP0.10			1,290
	FIDELITY NATL FINL INC			459
	FIDELITY NATL INFORMATION SVCS INC COM STK			1,231
	FIRST AMERN FINL CORP COM STK			225
	FIRST CTZNS BANCSHARES INC N C CL A CL A			474
	FIRST HAWAIIAN INC COM			102
	FIRST HORIZON CORPORATION COM			272
	FIRST SOLAR INC COM			634
	FIRSTENERGY CORP COM			692
	FLEETCOR TECHNOLOGIES INC COM			49
	FLOWERS FOODS INC COM			148
	FLOWERVE CORP COM			187
	FMC CORP COM (NEW)			232
	FORTIVE CORP COM MON STOCK			901
	FORTREA HLDGS INC COM			107
	FORTUNE BRANDS INNOVATIONS INC USD0.01			334
	FOX CORP CL A CL A			254
	FOX CORP CL B CL B			124
	FRESHPET INC COM			94
	FRKLN RES INC COM			295
	FRONTIER COMMUNICATIONS PARENT INC COM NPV			215
	FTI CONSULTING INC COM			186

GALLAGHER ARTHUR J & CO COM	1,553
GAMESTOP CORP NEW CL A	162
GAP INC COM	141
GARMIN LTD COMMON STOCK	682
GATES INDL CORP PL COM USD0.01	52
GEN DIGITAL INC COM USD0.01	370
GENERAC HLDGS INC COM STK	272
GENPACT LIMITED	160
GENTEX CORP COM	264
GENUINE PARTS CO COM	672
GINKGO BIOWORKS HOLDINGS INC COM	82
GLOBAL PMTS INC COM	1,133
GLOBALFOUNDRIES INC	164
GLOBE LIFE INC COM	370
GLOBUS MED INC CL A NEW COM STK	155
GODADDY INC CL A CL A	213
GRACO INC COM	296
GRAND CANYON ED INC COM STK	98
GRAPHIC PACKAGING HLDG CO COM STK	120
GROCERY OUTLET HLDG CORP COM	88
GUIDEWIRE SOFTWARE INC COM USD0.0001	308
GXO LOGISTICS INC COM	247

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	HALLIBURTON CO COM			897
	HANOVER INS GROUP INC COM			150
	HARLEY DAVIDSON COM USD0.01			164
	HARTFORD FINL SVCS GROUP INC COM			821
	HASBRO INC COM			231
	HASHICORP INC COM USD0.000015 CL A			25
	HAWAIIAN ELEC INDS INC COM			54
	HAYWARD HLDGS INC COM			62
	HEICO CORP NEW CL A CL A			38
	HEICO CORP NEW COM			27
	HENRY SCHEIN INC COMMON STOCK			340
	HERTZ GLOBAL HLDGS INC NEW COM			47
	HESS CORP COM STK			613
	HEWLETT PACKARD ENTERPRISE CO COM			751
	HEXCEL CORP NEW COM			215
	HF SINCLAIR CORPORATION COM USD0.01			277
	HILTON WORLDWIDE HLDGS INC COM			849
	HOLOGIC INC COM			599
	HORMEL FOODS CORP COM			321
	HOULIHAN LOKEY INC CL A CL A			196
	HOWARD HUGHES HLDGS INC COM			99
	HOWMET AEROSPACE INC COM USD1.00			710
	HP INC COM			716
	HUBBELL INC COM			332
	HUNT J B TRANS SVCS INC COM			456
	HUNTINGTON BANCSHARES INC COM			634
	HUNTINGTON INGALLS INDS INC COM			352
	HUNTSMAN CORP COM STK			147
	HYATT HOTELS CORP COM CL A COM CL A			197
	IAC INC COM NEW			134
	ICON PLC COM			678
	ICU MED INC COM			70
	IDACORP INC COM			170

IDEX CORP COM	522
ILLUMINA INC COM	535
INCYTE CORP COM	104
INFORMATICA INC CL A CL A	39
INGERSOLL RAND INC COM	1,081
INGREDION INC COM	248
INTEGRA LIFESCIENCES HLDG CORP COM DESP	103
INTERACTIVE BROKERS GROUP INC CL COM	299
INTERPUBLIC GROUP COMPANIES INC COM	436
INTL FLAVORS & FRAGRANCES INC COM	715
INTL PAPER CO COM	434
INVESCO LTD COM STK USD0.20	225
IONIS PHARMACEUTICALS INC COM	35
IPG PHOTONICS CORP COM	112
IQVIA HLDGS INC COM USD0.01	107
IRIDIUM COMMUNICATIONS INC COM STK	12
ITT INC COM	341
JABIL INC COM USD0.001	204
JACK HENRY & ASSOC INC COM	281
JACOBS SOLUTIONS INC COM	564
JANUS HENDERSON GROUP PLC	141

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date &	(d) Cost **	(e) Current
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest		value
	Common stock - continued			
	JAZZ PHARMACEUTICALS PLC COM			124
	JEFFERIES FINL GROUP INC COM			255
	JONES LANG LASALLE INC COM STK			308
	JUNIPER NETWORKS INC COM			325
	KARUNA THERAPEUTICS INC COM			41
	KBR INC COM			163
	KELLANOVA COM USD0.25			504
	KEMPER CORP DEL COM			102
	KEYCORP NEW COM			465
	KEYSIGHT TECHNOLOGIES INC COM			726
	KIRBY CORP COM			160
	KKR & CO INC CL A CL A			1,434
	KNIGHT-SWIFT TRANSN HLDGS INC CL A			311
	KOHL'S CORP COM			110
	KROGER CO COM			1,032
	KYNDRYL HLDGS INC COM			163
	LAB CORP AMER HLDGS COM NEW			668
	LAMAR ADVERTISING CO NEW CL A CL A			74
	LAMB WESTON HLDGS INC COM USD5			30
	LANDSTAR SYS INC COM			48
	LEAR CORP COM NEW COM NEW			282
	LEGGETT & PLATT INC COM			121
	LEIDOS HLDGS INC COM			511
	LENNAR CORP CL A CL A			1,265
	LENNAR CORP CL B CL B			60
	LENNOX INTL INC COM			495
	LIBERTY BROADBAND CORP COM SER A COM SERA			35
	LIBERTY BROADBAND CORP COM SER C COM SERC			258
	LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER A			48
	LIBERTY MEDIA CORP DEL COM LIBERTY FORMULA ONE SER C			423
	LIBERTY MEDIA CORP DEL COM LIBERTY SIRIUSXM SER A			74

LIBERTY MEDIA CORP DEL COM LIBERTY SIRIUSXM SER C	153
LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER A	25
LIBERTY MEDIA CORP DEL COM LIBERTY LIVE SER C	60
LINCOLN ELEC HLDGS INC COM	27
LINCOLN NATL CORP COM	144
LITHIA MTRS INC COM CL A	307
LITTELFUSE INC COM	223
LIVE NATION ENTERTAINMENT INC	391
LKQ CORP COM LKQ CORP	440
LOEWS CORP COM	441
LOUISIANA-PACIFIC CORP COM	157
LUCID GROUP INC COM	108
LUMENTUM HLDGS INC COM	121
LYONDELLBASELL IND N V COM	851
M & T BK CORP COM	785
MACYS INC COM STK	188
MADISON SQUARE GARDEN SPORTS	117
MANPOWERGROUP INC	136
MAPLEBEAR INC COM	5
MARATHON OIL CORP COM	504
MARAVAI LIFESCIENCES HLDGS INC CL A	10
MARKEL GROUP INC	645
MARRIOTT VACATIONS WORLDWIDE CORP COM	105

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date &	(d) Cost **	(e) Current value
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest		
	Common stock - continued			
	MARTIN MARIETTA MATLS INC COM			1,063
	MARVELL TECHNOLOGY INC COM			1,782
	MASCO CORP COM			522
	MASTEC INC COM			163
	MATCH GROUP INC NEW COM			35
	MATTEL INC COM STOCK			229
	MC CORMICK & CO INC COM NON-VTG			595
	MDU RES GROUP INC COM			139
	MERCURY SYSTEMS INC			68
	MGIC INVT CORP WIS COM			184
	MGM RESORTS INTERNATIONAL COM			436
	MICROCHIP TECHNOLOGY INC COM			483
	MIDDLEBY CORP COM			271
	MIRATI			111
	MISTER CAR WASH INC COM			23
	MKS INSTRS INC COM			237
	MOHAWK INDS INC COM			189
	MOLINA HEALTHCARE INC COM			327
	MOLSON COORS BEVERAGE COMPANY COM USD0.01 CLASS B			370
	MOSAIC CO/THE			408
	MP MATERIALS CORP COM USD0.0001 CL A			71
	MSA SAFETY INC COM			179
	MSC INDL DIRECT INC CL A COM			165
	MSCI INC COM USD0.01			753
	MURPHY USA INC COM			12
	NASDAQ INC			688
	NATL FUEL GAS CO COM			153
	NCINO INC NEW COM			74
	NCR ATLEOS CORPORATION COM USD0.01 WI			54
	NCR VOYIX CORP COM STK USD0.01			75
	NETAPP INC COM STK			388
	NEW YORK CMNTY BANCORP INC COM			252
	NEW YORK TIMES CO CL A			273
	NEWELL BRANDS INC COM			115

NEWMARKET CORP COM	118
NEWS CORP COM CL A	325
NEWS CORP COM CL B	101
NEXSTAR MEDIA GROUP INC COMMON STOCK	119
NISOURCE INC COM	380
NORDSON CORP COM	522
NORDSTROM INC COM	73
* NORTHERN TR CORP COM	599
NORWEGIAN CRUISE LINE HLDGS LTD COM	222
NOV INC COM	276
NRG ENERGY INC COM NEW	406
NU HOLDINGS LTD	212
NUCOR CORP COM	1,496
NUTANIX INC CL A CL A	304
NVENT ELECTRIC PLC COM USD0.01 WI	336
NVR INC COM STK USD0.01	651
OGE ENERGY CORP COM	242
OKTA INC CL A CL A	448
OLAPLEX HLDGS INC COM	11
OLD DOMINION FREIGHT LINE INC COM	94

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
Common stock - continued				
	OLD REPUBLIC INTERNATIONAL CORP COM STK USD1			267
	OLIN CORP COM			228
	OLLIES BARGAIN OUTLET HLDGS INC COM			109
	OMNICOM GROUP INC COM			591
	ON SEMICONDUCTOR CORP COM			1,245
	ONEMAIN HLDGS INC COM			192
	ONEOK INC COM STK			1,334
	ORGANON & CO COM			128
	OSHKOSH CORPORATION			244
	OTIS WORLDWIDE CORP COM USD0.01 WI			1,205
	OVINTIV INC COM USD0.01			216
	OWENS CORNING NEW COM STK			454
	PACCAR INC COM			1,732
	PACKAGING CORP AMER COM			498
	PARAMOUNT GLOBAL COM USD0.001 CL A			6
	PARAMOUNT GLOBAL OM USD0.001 CL B			295
	PARKER-HANNIFIN CORP COM			2,036
	PAYCOR HCM INC COM			26
	PENN ENTERTAINMENT INC			135
	PENSKE AUTOMOTIVE GROUP INC COM STK			108
	PENTAIR PLC COM USD0.01			413
	PERFORMANCE FOOD GROUP CO COM			193
	PERRIGO COMPANY LIMITED COM EUR0.001			150
	PETCO HEALTH & WELLNESS CO INC CL A COM			9
	PG& E CORP COM			1,269
	PHILLIPS 66 COM			2,049
	PHINIA INC COM USD0.01 WI			49
	PILGRIMS PRIDE CORP			39
	PINNACLE FINL PARTNERS INC COM			227
	PINNACLE W. CAP CORP COM			282
	PLANET FITNESS INC CL A CL A			112
	PLAYTIKA HLDG CORP COM			1

PLUG PWR INC COM NEW	82
POLARIS INC	161
POPULAR INC COM NEW COM USD6 (POST REV SPLIT)	200
POST HLDGS INC COM STK	156
PPG IND INC COM	910
PPL CORP COM ISIN US69351T1060	692
PREMIER INC CL A CL A	92
PRIMERICA INC COM	89
PRINCIPAL FINL GROUP INC COM STK	659
PROSPERITY BANCSHARES INC COM	205
PRUDENTIAL FINL INC COM	1,304
PTC INC COM	330
PUB SERVICE ENTERPRISE GROUP INC COM	1,052
PULTE GROUP INC	763
PURE STORAGE INC CL A CL A	76
PVH CORP COM USD1	254
QIAGEN	347
QORVO INC COM	382
QUANTA SVCS INC COM	790
QUANTUMSCAPE CORP COM USD0.0001 CL A	81
QUEST DIAGNOSTICS INC COM	535
QUIDELORTHO CORPORATION	135

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date &	(d) Cost **	(e) Current value
(a)	(b) Identity of issue, borrower, lessor, or similar party	range of interest		
	Common stock - continued			
	R1 RCM INC NEW			56
	RALPH LAUREN CORP CL A CL A			200
	RANGE RES CORP COM			246
	RAYMOND JAMES FNCL INC COM STK			731
	RB GLOBAL INC			98
	RBC BEARINGS INC COM			278
	REGAL REXNORD CORPORATION COM STK			338
	REGIONS FINL CORP NEW COM			628
	REINSURANCE GROUP AMER INC COM NEW STK			371
	RELIANCE INC COM NPV			559
	RENAISSANCE RE HLDGS LTD COM			250
	REPLIGEN CORP COM STK USD0.01			193
	REPUBLIC SVCS INC COM			1,178
	REVVITY INC			469
	REYNOLDS CONSUMER PRODS INC COM			51
	RH COM			131
	RIVIAN AUTOMOTIVE INC			538
	RLI CORP COM			144
	ROBERT HALF INC COM USD0.001			314
	ROBINHOOD MKTS INC COM CL A COM CL A			296
	ROCKET COS INC CL A CL A			39
	ROIVANT SCIENCES LTD COM			8
	ROKU INC COM CL A COM CL A			342
	ROSS STORES INC COM			107
	ROYAL CARIBBEAN GROUP COM STK			732
	ROYAL GOLD INC COM STK USD0.01			276
	ROYALTY PHARMA PLC COM CLASS A			362
	RPM INTL INC			397
	RYDER SYS INC COM			174
	S.W. AIRL CO COM			594
	SAIA INC COM STK			357
	SCHNEIDER NATL INC WIS CL B CL B			47
	SCIENCE APPLICATIONS INTL CORP NEW COM			227

SEABOARD CORP DEL COM	25
SEALED AIR CORP NEW COM STK	81
SEI INVTS CO COM	222
SENSATA TECHNOLOGIES B V HOLDING	196
SENTINELONE INC CL A COM CL A COM	192
SERVICE CORP INTL COM	222
SILGAN HLDGS INC COM	130
SIRIUS XM HLDGS INC COM	122
SITEONE LANDSCAPE SUPPLY INC COM	169
SKECHERS U S A INC CL A CL A ISIN	266
SKYWORKS SOLUTIONS INC COM	619
SLM CORP COM	92
SMITH A O CORP COM	308
SMUCKER J M CO COM NEW	450
SNAP-ON INC COM	520
SOFI TECHNOLOGIES INC COM	321
SONOCO PROD CO COM	189
SOTERA HEALTH CO COM	17
SOUTHWESTERN ENERGY CO COM	247
SPECTRUM BRANDS HLDGS INC COM	
USD0.01	96
SPIRIT AEROSYSTEMS HLDGS INC CL A	103

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	SS&C TECHNOLOGIES HLDGS INC COM			461
	SSR MNG INC			75
	STANLEY BLACK & DECKER INC COM			520
	STATE STR CORP COM			827
	STEEL DYNAMICS INC COM			637
	STERICYCLE INC COM			158
	STERIS PLC ORD USD0.001			754
	STIFEL FINL CORP COM			239
	SUNRUN INC COM			143
	SYNCHRONY FINL COM			545
	SYNOVUS FINL CORP COM NEW COM NEW			190
	T ROWE PRICE GROUP INC			823
	TAKE-TWO INTERACTIVE SOFTWARE INC COM STK USD0.01			918
	TANDEM DIABETES CARE INC COM NEW COM USD0.001(POST REV SPLT)			57
	TAPESTRY INC COM USD0.01			273
	TD SYNnex CORPORATION COM USD0.001			195
	TECHNIPFMC PLC COM USD1			301
	TELADOC HEALTH INC			123
	TELEDYNE TECHNOLOGIES INC COM			718
	TELEFLEX INC COM			405
	TEMPUR SEALY INTL INC			235
	TENET HEALTHCARE CORP COM NEW .			264
	TERADYNE INC COM			97
	TETRA TECH INC NEW COM			250
	TEXTRON INC COM			543
	TFS FINL CORP COM STK			27
	THOR INDS INC COM STK			209
	TIMKEN CO COM			169
	TOLL BROS INC COM			381
	TOPBUILD CORP COM			383
	TPG PARTNERS LLC CL A COM			70
	TRADEWEB MKTS INC CL A CL A			237
	TRANE TECHNOLOGIES PLC COM USD1			1,354
	TRANSDIGM GROUP INC COM			1,540

TRANSUNION COM	459
TRAVEL + LEISURE CO COM USD0.01	53
TRIMBLE INC COM TRIMBLE INC	453
TRIPADVISOR INC COM USD0.001	79
TWILIO INC CL A CL A	371
TYLER TECHNOLOGIES INC COM STK	146
TYSON FOODS INC CL A COM (DELAWARE)	517
UBIQUITI INC COM	3
UGI CORP NEW COM	179
U-HAUL HOLDING COMPANY	150
U-HAUL HOLDING COMPANY	12
UIPATH INC CL A CL A	76
UNDER ARMOR INC CL A	58
UNDER ARMOUR INC CL C COM	57
UNITED AIRLINES HOLDINGS INC COM USD0.01	466
UNITED RENTALS INC COM	1,067
UNITED STS STL CORP NEW COM	372
UNITED THERAPEUTICS CORP DEL COM STK	343
UNITY SOFTWARE INC COM	250
UNIVERSAL DISPLAY CORP COM	169

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	UNUM GROUP			307
	UNVL HEALTH SERVICES INC CL B COM			316
	US FOODS HLDG CORP COM			356
	UWM HLDGS CORP COM USD0.0001 CL A			16
	V F CORP COM			228
	VAIL RESORTS INC COM			251
	VALMONT INDS INC COM			157
	VALVOLINE INC COM			134
	VERISIGN INC COM			600
	VERTIV HOLDINGS LLC COM USD0.0001			528
	VESTIS CORP COM			86
	VIASAT INC COM			113
	VIATRIS INC			448
	VICTORIAS SECRET & CO COM			39
	VIRTU FINL INC CL A CL A			63
	VISTRA CORP COM USD0.01			343
	VONTIER CORP COM USD0.0001 WI			123
	VOYA FINL INC COM			249
	VULCAN MATERIALS CO COM			810
	WABTEC CORP COM			782
	WALGREENS BOOTS ALLIANCE INC COM			648
	WARNER BROS DISCOVERY INC			867
	WATSCO INC COM			369
	WAYFAIR INC CL A CL A			114
	WEBSTER FNCL CORP WATERBURY CONN COM			301
	WEC ENERGY GROUP INC COM			919
	WESCO INTL INC COM			266
	WESTERN ALLIANCE BANCORPORATION COM			246
	WESTERN UNION CO			129
	WESTLAKE CORPORATION COM USD0.01			155
	WESTN DIGITAL CORP COM			587
	WESTROCK CO COM			365
	WEX INC COM			155
	WHIRLPOOL CORP COM			226

WHITE MOUNTAINS INSURANCE GROUP	128
WILLIAMS CO INC COM	1,468
WILLIAMS SONOMA INC COM	387
WILLIS TOWERS WATSON PLC COM	756
WILLSCOT MOBILE MINI HLDGS CORP COM	221
WINTRUST FINL CORP COM	196
WK KELLOGG CO COM	30
WOLFSPEED INC COM	187
WOODWARD INC COM	281
WYNDHAM HOTELS & RESORTS INC COM	209
WYNN RESORTS LTD COM	308
XCEL ENERGY INC COM	1,179
XP INC COM	268
XPO INC COM	345
XYLEM INC COM	826
YUM BRANDS INC COM	156
ZEBRA TECHNOLOGIES CORP CL A	397
ZILLOW GROUP INC COM	106
ZILLOW GROUP INC COM CLASS C	311
ZIMMER BIOMET HLDGS INC COM	885

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Common stock - continued			
	ZIONS BANCORPORATION N A			221
	ZOOM VIDEO COMMUNICATIONS INC CL A			632
	ZOOMINFO TECHNOLOGIES INC COM			93
	Total Common stock			5,071,247
	Mutual fund			
	PIMCO ALL ASSET FUND			112,479
	REITs			
	1ST INDL RLTY TR INC COM			240
	AGNC INVT CORP COM			221
	AGREE RLTY CORP COM			214
	ALEXANDRIA REAL ESTATE EQUITIES INC COM			752
	AMERICAN HOMES 4 RENT COMMON STOCK			412
	AMERICOLD RLTY TR INC COM			283
	ANNALY CAPITAL MANAGEMENT INC COM NEW COM USD0.01(POST REV SPLT)			332
	AVALONBAY CMNTYS REIT			917
	BRIXMOR PPTY GROUP INC COM			242
	BSTN PPTYS INC			382
	CAMDEN PPTY TR SH BEN INT			356
	COUSINS PPTYS INC			129
	CUBESMART			359
	DIGITAL RLTY TR INC COM			1,405
	EASTGROUP PPTYS INC REIT			289
	EPR PPTYS COM SH BEN INT COM SH BEN INT			125
	EQTY LIFESTYLE PPTYS INC REIT			292
	EQTY RESDNTL EFF 5/15/02			789
	ESSEX PPTY TR REIT			548
	EXTRA SPACE STORAGE INC COM			1,159
	FEDERAL RLTY INVT TR COM USD0.01			289
	GAMING & LEISURE PPTYS INC COM			437

HEALTHCARE REALTY TRUST INC COM	227
USD0.01 CL A	376
HEALTHPEAK OP LLC	84
HIGHWOODS PPTYS INC COM	475
HOST HOTELS & RESORTS INC REIT	720
INVITATION HOMES INC COM	355
IRON MTN INC NEW COM	161
KILROY RLTY CORP COM	447
KIMCO REALTY CORPORATION	101
MEDICAL PPTYS TR INC COM REIT	540
MID-AMER APT CMNTYS INC COM	116
NATIONAL STORAGE AFFILIATES TR COM	9
SHS BEN INT COM SHS BEN INT	271
NET LEASE OFFICE PPTYS COM	260
NNN REIT INC	113
OMEGA HEALTHCARE INVS INC REIT	170
PARK HOTELS & RESORTS INC COM	213
RAYONIER INC REIT	1,437
REALTY INCOME	418
REALTY INCOME CORP COM	407
REGENCY CTRS CORP COM	179
REXFORD INDL RLTY INC COM	847
RITHM CAPITAL CORP	1,253
SBA COMMUNICATIONS CORP	247
SIMON PROPERTY GROUP INC COM	
STAG INDL INC COM	

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
REITs - continued				
	STARWOOD PROPERTY TRUST INC COM REIT			216
	SUN COMMUNITIES INC COM			443
	UDR INC COM STK			411
	VENTAS INC REIT			689
	VICI PPTYS INC COM			1,138
	VORNADO RLTY TR COM			174
	W P CAREY INC COM			476
	WELLTOWER INC COM REIT			1,673
	WEYERHAEUSER CO COM			879
	Total REITs			25,697
Collective trust funds				
	BLACKROCK INTERNATIONAL MULTI CAP EQUITY FUND			114,279
	CAPITAL GROUP EUROPACIFIC GROWTH TRUST			355,375
	CAPITAL GROUP GROWTH FUND OF AMERICA TRUST			1,091,473
	CAPITAL GROUP WASHINGTON MUTUAL INVESTORS TRUST			343,658
	GW&K SMALL-MID CAP CORE EQUITY FUND			163,769
*	NORTHERN TRUST COLLECTIVE ACWI ex-U.S. INDEX FUND			147,105
*	NORTHERN TRUST COLLECTIVE SHORT TERM INVESTMENT FUND			9,767
	SSGA RUSSELL SMALL/MID CAP INDEX FUND CLASS K			791,167
	SSGA S&P 500 INDEX FUND CLASS K			1,828,282
	SSGA U.S. BOND INDEX FUND CLASS K			143,794
	SSGA TARGET RETIREMENT 2020			208,428
	SSGA TARGET RETIREMENT 2025			406,148
	SSGA TARGET RETIREMENT 2030			511,724
	SSGA TARGET RETIREMENT 2035			489,296
	SSGA TARGET RETIREMENT 2040			407,718
	SSGA TARGET RETIREMENT 2045			354,113

SSGA TARGET RETIREMENT 2050	284,105
SSGA TARGET RETIREMENT 2055	179,847
SSGA TARGET RETIREMENT 2060	94,271
SSGA TARGET RETIREMENT 2065	26,612
SSGA TARGET RETIREMENT INCOME	123,938
Total Collective trust funds	8,074,869

Futures contracts

EQUITY FUTURES OFFSET - LONG	(803)
FUT MAR 24 EMINI S&P 500	241
FUT MAR 24 IMMEMINI MDCP	562
Total Futures contracts	-

Corporate debt

AERCAP IRELAND CAP 2.875% DUE 08-14-2024	1,864
AERCAP IRELAND CAP/GLOBA 1.65% DUE 10-29-2024 BEO	3,088
AMERN HONDA FIN FLTGT RT 1.706417% 06-07-2024	6,604
APIDOS CLO XXVII / APIDOS CLO XXVII SR SECD NT CL A-1R 144A 6.50814% 07-17-2030	3,245
BANCO SANTANDER S 2.706% DUE 06-27-2024	2,960
BANK AMER CORP BANK FLTGT RT 02-04-2025	1,099
BANK OF AMERICA CORPORATION 1.843% 02-04-2025	2,988
BANK OF NOVA SCOTIA 2YR FRN NEW ISSUE FLTGT RT 03-11-2024	3,002
BARCLAYS PLC 3.65% DUE 03-16-2025	2,444
BAXTER INTL INC FLT RT DUE 11-29-2024/06-14-2022 BEO	998
BOEING CO 1.433% 02-04-2024	2,390
CAPITAL ONE FINL CORP 05-09-2025	1,999
CARLYLE GLOBAL MARKET STRATEGI 14/08/2030 0% 08-14-2030	2,510

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Corporate debt - continued			
	CHARTER COMMUNICATIONS OPER LLC FRNS 02-01-2024			1,000
	CHASE AUTO OWNER TR 2023-A ASSET BACKED NT CL A-2 144A 5.9% 03-25-2027			3,015
	CIGNA GRP NEW DISC COML PAPER 4/2 YRS 1&2 01-16-2024			7,778
	CONSTELLATION BRANDS INC DISC COML PAPER4/A2 YRS 1&2 01-08-2024			7,688
	CONSTELLATION ENERGY GENERATION LLC DISCCOML PAPER 4/2 YRS 1&2 01-09-2024			7,787
	CREDIT SUISSE AG NEW YORK BRH MEDIUM TER4.75% DUE 08-09-2024 REG			4,969
	DELL EQUIP FIN TR 2021-2 ASSET BACKED NTCL A-3 144A .53% 12-22-2026			413
	DEUTSCHE BK AG N Y BRANCH 3.961% 11-26-2025			1,967
	ELLINGTON FINL MTG TR 2022-1 MTG PASS THRU CTF CL A-1 2.206% 01-25-2067			2,162
	ENERGY TRANSFER L P DISC COML PAPER 4/2 YRS 1&2 01-04-2024			10,690
	ERAC USA FINANCE LLC 01-08-2024			6,490
	FIDELITY NATL INFORMATION SVCS INC DISC COML PAPER 4/2 YRS 1&2 01-05-2024			4,195
	FIDELITY NATL INFORMATION SVCS INC DISC COML PAPER 4/2 YRS 1&2 01-16-2024			2,692
	FORD CR AUTO LEASE TR 2023-B FLTGT RT SR 23-B CL A2B 02-15-2026			4,500
	FORD CR AUTO OWNER FLTGT RT 6.07864% DUE 08-15-2025			1,236
	GEORGIA PWR CO FLTGT RT 05-08-2025			3,007
	GLOBAL PMTS INC 1.5% 11-15-2024			3,857
	GOLDMAN SACHS FLTGT RT 6.102014% DUE 12-09-2026			3,365
	GOLDMAN SACHS GROUP INC 5.7% DUE 11-01-2024 BEO			1,904
	GS MTG BACKED SECS 5% DUE 01-25-2052			2,375
				994

HALEON US CAPITAL LLC 3.024% 03-24-2024	
HUMANA INC DISC COML PAPER 4/2 YRS 1&2 01-02-2024	5,798
HUMANA INC DISC COML PAPER 4/2 YRS 1&2 01-03-2024	1,999
HYUNDAI AUTO RECEIVABLES TR 2022-C NT CLA-2-B FLTG RATE 6.09864% 11-17-2025	2,062
INTERCONTINENTAL EXCHANGE INC 4/A2 DISC COML PAPER 01-03-2024	3,098
INTERCONTINENTAL EXCHANGE INC 4/A2 DISC COML PAPER YRS 1&2 01-05-2024	250
JPMORGAN CHASE & CO FLTG RT DUE 06-14-2025/06-14-2024 REG	2,003
KINDER MORGAN INC DISC COML PAPER 4/2 YRS 1&2 01-22-2024	7,372
L3HARRIS TECHNOLOGIES INC 0% CP 01-16-2023	7,779
LCM XIII LTD PARTNERSHIP / LCM XIII 0% 07-19-2027	139
MARATHON STATIC FLTG RT 7.06781% DUE 07-20-2030	2,396
MFA 2020-NQM2 TR 1.381% DUE 04-25-2065	430
MIZUHO FINL GROUP INC FLTG 05-22-2026	2,199
NAVIENT PRIVATE ED LN TR 2020-I 6.43981%04-15-2069	1,410
NEUBERGER BERMAN CLO LTD 20/04/2031 1.29400002956% 04-21-2031	3,899
NEXTERA ENERGY CAP HLDGS INC SR NT FLTG RATE 6.371814% 03-21-2024	300
NOMURA HLDGS INC 2.648% 01-16-2025	1,067
OBX 2022-NQM1 TR MTG BACKED NT CL A-1 144A 2.30500006676% 11-25-2061	1,999
OBX 2022-NQM2 TR VAR RT 2.783% DUE 01-25-2062	664
OSCAR US FDG XIV LLC NT CL A-2 144A 1.6%03-10-2025	26
PAC GAS & ELEC CO FIXED 3.75% DUE 02-15-2024	199
PACIFIC GAS & ELEC CO 3.4% 08-15-2024	295
PVTPL APIDOS CLO 17-26A A1AR FLTG 07-18-2029 USD	1,613
PVTPL BAMLL COML MTG SECS SR 2019- AHT CL A FLTG 03-15-2034	694
PVTPL BANK OF AMERICA AUTO TRUST SER 23-2A CL A2 5.85% 08-17-2026	5,029
PVTPL BAYER US FINANCE LLC BNDS 3.375% 10-08-2024 BEO	3,929
PVTPL CBAM 2018-8 LTD LLC NT CL A-1 FLTG 3C7 10-20-2029 BEO	2,162
PVTPL CMO AREIT 2021-CRE5 LTD/AREIT AREIT 2021-C SR NT CL A VAR RT 07-17-2026	1,956
PVTPL CMO COLT 2021-4 MTG LN TR MTG PASSTHRU CTF CL A-1 10-25-2066	1,847
	3,887

PVTPL GOLDEN TREE LN OPPORTUNITIES IX SER 14-9A CL AR2 FLTG 144A 10-29-2029	
PVTPL GPMT 2021-FL3 LTD/GPMT 2021- FL3 LLC SR SECD NT CL A FLTG 07-16-2035	1,047
PVTPL HALSEYPOINT CLO II LTD SR 20-2A CL A1 FLTG 07-20-2031	3,389
PVTPL HYUNDAI AUTO LEASE SECURITIZATION TR 202 FLTG RT SR 23-C CL A2B 03-16-2026	2,401
PVTPL JACKSON NATIONAL LIFE GLBL FUNDING FLTG RT 06-28-2024	2,605
PVTPL KKR CLO 9 LTD / KKR CLO 9 LLC 15/07/2030 VAR RT DUE 07-15-2030 BEO	2,035

Abbott Laboratories Stock Retirement Plan**EIN: 36-0698440, Plan Number: 334****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued****December 31, 2023****(Dollars in thousands)**

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
Corporate debt - continued				
	PVTPL M&T EQUIPMENT 2023-LEAF1 LLC 5.742% 08-15-2024			1,467
	PVTPL MAGNETITE XVIII LTD/MAGNETITE XVIII LL SR16-18A CL AR2 VAR RT 11-15-2028			163
	PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE LO SR 20-FL4 CL A VAR RT DUE 11-15-2035			1,225
	PVTPL MF1 MULTIFAMILY HOUSING MORTGAGE CO SER 21-FL7 CL A FLTG RT DUE 10-18-2036			3,948
	PVTPL NAVIENT PRIVATE ED REFI LN TR 2021-G CL A 1.58% DUE 04-15-2070 BEO			1,474
	PVTPL NAVIENT PRIVATE ED REFI LN TR SRS 20-HA CL A 1.31% DUE 01-15-2069			835
	PVTPL NAVIENT STUDENT LN TR 2014-1 SR 22-A CL A 2.23% 07-15-2070			1,095
	PVTPL NELNET STUDENT LN TR FLTG RT SER 19-2A CL A 06-27-2067 BEO			1,503
	PVTPL OCTAGON INVT PARTNERS XXI LTD/OCTAGON SR SECD NT 02-14-2031			3,494
	PVTPL PALMER SQUARE LN FDG 2021-3 LTD/SR SECD NT CL A-1 FLTG 5.04257% 07-20-2029			2,034
	PVTPL PALMER SQUARE LOAN FUNDING LTD SER 21-4A CL A1 FLTG RT 10-15-2029 BEO			1,646
	PVTPL SMBC AVIATION CAP FIN DAC 3.55% DUE 04-15-2024			4,369
	PVTPL SOFI CONSUMER LOAN PROGRAM SER 23-15 CL A 5.81% 05-15-2031			749
	PVTPL SOUND PT CLO XVI LTD/SOUND PT CLO XVI VAR RT DUE 07-25-2030 BEO			1,146
	PVTPL STANDARD CHARTERED PLC NT FLTG RATE 11-23-2025			4,576
	PVTPL STRATUS CLO 2021-3 LTD/STRATUS CLO202 SR 21-3A CL A VAR RT DUE 12-29-2029			206

PVTPL TCW CLO SER 18-1A CL A1R FLTG 04-25-2031 BEO	256
PVTPL TRILLIUM CR CARD TR II SR 23-3A CLA VAR RT DUE 08-26-2028 BEO	3,211
PVTPL UBS AG LONDON BRH 09/02/2024 5.72123% DUE 02-09-2024 BEO	700
PVTPL VENTURE CLO LTD SR 17-28A CL A2R VAR RT 07-20-2030	3,315
PVTPL VIBRANT CLO VI LTD SER 17-6A CL AR FLTG 06-20-2029	520
PVTPL VMC FIN 2021-FL4 LLC SR SECD NT CLA 144A FLTG RATE VAR RT DUE 06-16-2036	910
READY CAP MTG FING FLTG RT 6.43541% DUE 04-25-2038	664
SARANAC CLO VI LTD / SARANAC CLO VI 6.71659% 08-13-2031	1,808
SOFI PROFESSIONAL LN PROGRAM 2020-C POSTGRADUATE LN AST BKD NT 1.95% 02-15-2046	989
SOUND PT CLO XV LTD / SOUND PT CLO SR SECD NT CL A-RR 144A 6.47741% 01-23-2029	606
SOUTHERN CALIF EDISON CO 1ST & REF MTG FLTG RT 04-01-2024	2,225
SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-08-2024	3,494
SOUTHERN CALIF EDISON CO DISC COML PAPER4/2 YRS 1&2 01-17-2024	1,595
TOWD PT MTG TR 2021-1 NT CL A1 144A 2.25% 11-25-2061	1,787
TOYOTA AUTO RECEIVABLES OWNER TRUST SER 22-D CL A2B FLTG RT 01-15-2026	2,348
TOYOTA LEASE OWNER FLTG RT 5.87407% DUE 04-20-2026	3,400
V F CORP DISC COML PAPER 4/2 YRS 1&2 01-17-2024	4,486
VOLKSWAGEN AUTO FLTG RT 5.89407% DUE 01-20-2026	2,402
VW CR INC DISC COML PAPER 4/2 YRS 1&2 01-05-2024	4,995
WARNERMEDIA HLDGS INC SR NT NC1 3.788% 03-15-2025	882
WELLS FARGO & CO 2.406% 10-30-2025	973
WELLS FARGO & CO MEDIUM TERM SR NTS BOOKVAR RT DUE 04-25-2026/04-25-2025	2,317
Total Corporate debt	269,066
Government debt	
GNMA 2016-H17 MTG PASS THRU CTF CL MX FC08-20-2066	457
GNMA 2016-H20 REMIC PASSTHRU CTF CL MX-PT 09-20-2066	961
GNMA REMIC PASSTHRU SER 2016-H11 CLS F 05-20-2066	84
GNMA SR 23-H22 CL FB FLTG RT 09-20-2073	3,021

UNITED STATES OF AMER TREAS NOTES 3.875%DUE 03-31-2025	7,336
UNITED STATES OF AMER TREAS NOTES 4.875%DUE 10-31-2028	20,270
UNITED STATES TREASURY BILLS 04-11-2024	44
Total Government debt	32,173

Abbott Laboratories Stock Retirement Plan
EIN: 36-0698440, Plan Number: 334
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT
END OF YEAR) - Continued
December 31, 2023
(Dollars in thousands)

(a)	(b) Identity of issue, borrower, lessor, or similar party	(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
	Private 40-Act mutual funds	abc		
	PIMCO INTERNATIONAL PORTFOLIO			13,466
	PIMCO INVESTMENT GRADE CREDIT BOND PORTFOLIO			53,462
	PIMCO MUNICIPAL SECTOR PORTFOLIO			2,573
	PIMCO REAL RETURN PORTFOLIO			8,031
	PIMCO U.S. GOVERNMENT SECTOR PORTFOLIO			40,547
	PIMCO EMERGING MARKETS PORTFOLIO			9,285
	PIMCO HIGH YIELD PORTFOLIO			2,309
	PIMCO ASSET-BACKED SECURITIES PORTFOLIO			29,900
	PIMCO MORTGAGE PORTFOLIO			30,103
	PIMCO SHORT-TERM FLOATING NAV PORTFOLIO II			486,796
	Total Private 40-Act mutual funds			676,472
	Other			
	BUY TO OPEN REPO W/CITIGROUP 5.39% FROM 12-29-2023 TO 01-02-2024			9,800
		Interest rates 3.00% to 9.75%		
	Loans to participants	Maturing 2024 through 2047		94,074
				<u>14,365,877</u>

*Represents a party-in-interest transaction.

**Cost information omitted as all investments are fully participant directed.

**FINANCIAL STATEMENTS AND
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
ABBOTT LABORATORIES STOCK RETIREMENT PLAN (PUERTO RICO)
DECEMBER 31, 2023 and 2022**

C O N T E N T S

	Page
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM	3
FINANCIAL STATEMENTS	
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS	5
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS	6
NOTES TO FINANCIAL STATEMENTS	7
SUPPLEMENTAL SCHEDULE	
SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)	16

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Plan Administrator and Plan Participants
Abbott Laboratories Stock Retirement Plan (Puerto Rico)

Opinion on the financial statements

We have audited the accompanying statements of net assets available for benefits of Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) as of December 31, 2023 and 2022, the related statement of changes in net assets available for benefits for the year ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the net assets available for benefits of the Plan as of December 31, 2023 and 2022, and the changes in net assets available for benefits for the year ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America.

Basis for opinion

These financial statements are the responsibility of the Plan’s management. Our responsibility is to express an opinion on the Plan’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Plan in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Plan is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Plan’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Supplemental information

The schedule of assets (held at end of year) as of December 31, 2023 (“supplemental information”) has been subjected to audit procedures performed in conjunction with the audit of the Plan’s financial statements. The supplemental information is the responsibility of the Plan’s management. Our audit procedures included determining whether the supplemental information reconciles to the financial statements or the underlying accounting and other records, as applicable, and performing procedures to test the completeness and accuracy of the information presented in the supplemental information. In forming our opinion on the supplemental information, we evaluated whether the supplemental information, including its form and content, is presented in conformity with the Department of Labor’s Rules and Regulations for Reporting and Disclosure under the Employee Retirement Income Security Act of 1974. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the financial statements as a whole.

/s/ GRANT THORNTON LLP

We have served as the Plan’s auditor since 2014.

Chicago, Illinois
June 25, 2024

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENTS OF NET ASSETS AVAILABLE FOR BENEFITS
December 31, 2023 and 2022
(Dollars in thousands)

	2023	2022
Assets		
Cash	\$ -	\$ 5
Investments, at fair value	217,659	204,193
Notes receivable from participants	5,172	4,359
Due from brokers	16	-
Accrued interest income	54	33
Total assets	222,901	208,590
Liabilities		
Cash overdraft	21	-
Accrued expenses	1	-
Due to brokers	3	1
Total liabilities	25	1
NET ASSETS AVAILABLE FOR BENEFITS	<u>\$ 222,876</u>	<u>\$ 208,589</u>

The accompanying notes are an integral part of these statements.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR BENEFITS
Year ended December 31, 2023
(Dollars in thousands)

Additions	
Contributions	
Employer	\$ 2,430
Participant	4,987
	<u>7,417</u>
Total contributions	7,417
Investment income	
Net appreciation in fair value of investments	15,580
Interest and dividends	4,274
	<u>19,854</u>
Net investment income	19,854
Interest income on notes receivable from participants	233
	<u>27,504</u>
Net additions	27,504
Deductions	
Benefits paid to participants	13,196
Other expenses	21
	<u>13,217</u>
Total deductions	13,217
NET INCREASE	14,287
Net assets available for benefits	
Beginning of year	208,589
End of year	<u><u>\$ 222,876</u></u>

The accompanying notes are an integral part of this statement.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN

The following description of the Abbott Laboratories Stock Retirement Plan (Puerto Rico) (the “Plan”) provides only general information. Participants should refer to the Plan document for a more complete description of the Plan’s provisions.

General

The Plan was established January 1, 2013 in conjunction with Abbott Laboratories (“Abbott”) separating into two publicly traded companies - Abbott and AbbVie Inc. (“AbbVie”). The Plan covers employees of Abbott’s selected subsidiaries and affiliates in Puerto Rico (the “Company”).

The Plan is a profit-sharing plan containing a cash or deferred arrangement intended to qualify for favorable tax treatment under sections 1081.01 (a) and (d) of the Puerto Rico Internal Revenue Code of 2011, as amended. In addition, the Plan provides an arrangement by which employees may invest in Abbott shares. Employees of the Company may, after meeting certain employment requirements, voluntarily participate in the Plan. Beginning March 2017, newly hired employees in certain specified Abbott divisions and business units became eligible to participate in the Plan under a different structure (“Abbott Green” employees).

The Plan’s sponsor is Abbott Healthcare (Puerto Rico) Ltd. Alight Solutions serves as the record keeper of the Plan. The Northern Trust Company (“Custodian”) and Banco Popular de Puerto Rico (“Trustee”) serve as the Plan’s custodian and trustee, respectively. The Plan is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”).

Contributions and Vesting

Contributions to the Plan are paid to a trust administered by the Trustee. An investment committee (the “Committee”) may direct the Trustee to establish investment options of the Committee’s choosing.

Employees are eligible to commence participation in the Plan on any entry date following their date of hire. Eligible employees electing to participate may contribute from 2% (or 1%, for Abbott Green participants) to 25% of their eligible earnings, subject to certain limitations. Participants may choose to make their contributions from either pretax earnings or after-tax earnings, or both. Participants who have attained age 50 before the end of the Plan year and who are making the maximum pretax contribution are eligible to make catch-up contributions. Participants may elect to invest their contributions in any or all of the investment options, except for investment options closed to new contributions.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Contributions and Vesting - Continued

Employer matching contributions to the Plan are made each payroll period based on the participating employees' eligible earnings. Excluding the Abbott Green participants, the employer contribution for the year ended December 31, 2023 was 5% of the participant's eligible earnings if the participant elected to contribute at least 2% of eligible earnings to the Plan. Effective with the first pay period ending after March 1, 2017, employer matching contributions for Abbott Green participants are made at the rate of 100% up to a 3% deferral of eligible earnings. Employer contributions are invested each pay period according to the participant's investment elections.

In connection with the January 1, 2013 separation of Abbott into two publicly traded companies, Abbott shareholders received as a tax-free distribution one share of AbbVie stock for every share of Abbott held as of the close of business on December 12, 2012, the record date for the distribution. Plan participants may continue to hold the AbbVie stock they received from the distribution; however, they may not make new contributions or transfer existing contributions or earnings to purchase AbbVie stock in the Plan. AbbVie dividends are invested in the Plan's default investment option.

Participants may direct the Trustee to sell all or a portion of the Abbott and AbbVie common shares held in their accounts and reinvest the proceeds in any of the other investment options available to the participants.

Participants are at all times fully vested in their own contributions and earnings thereon. Vesting in employer contributions and earnings thereon is based on the following vesting schedule:

Service	Vesting percentage
Less than two years	0%
Two years or more	100%

A participant becomes 100% vested in his or her employer contributions if, while employed by the Company, he or she dies or attains age 65.

Abbott Green participants who first became participants prior to January 1, 2018 are also fully vested in matching contributions upon qualifying disability.

Non-vested portions of employer contributions and earnings thereon are forfeited as of an employee's termination date. Forfeitures are used to (1) restore any forfeitures of participants who returned to service with the Company within a given period of time, (2) pay Plan expenses as deemed appropriate by the Administrator, and (3) reduce future employer contributions if terminated participants do not return to service within the given period of time. In 2023, approximately \$106,400 of forfeitures were used to reduce employer contributions. Forfeitures totaling approximately \$118,200 and \$113,400 were available at the end of 2023 and 2022, respectively.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE A - DESCRIPTION OF THE PLAN - Continued

Distributions and In-Service Withdrawals

Following retirement, termination or death, participants or their beneficiaries may elect to receive a distribution in installments, a single lump sum or a partial lump sum. Participants may elect a direct rollover of their accounts. Interest, dividends and other earnings will continue to accrue on any deferred amounts prior to distribution.

Prior to termination, participants are permitted to withdraw their after-tax contributions (after-tax contributions made on or after January 8, 2016 may be withdrawn from the Plan only after being held for two or more years) and rollover contributions (including merged-in plan rollover accounts) and, after age 59 $\frac{1}{2}$, may also withdraw pretax contributions. Distributions are made in cash or, to the extent contained in the participant's account, a participant may elect distribution of Abbott and AbbVie common shares, and in each case, are subject to certain limitations.

Notes Receivable from Participants

Participants may convert their vested account balances into one or two loans to themselves. The borrowing may not exceed the lesser of the current market value of the assets allocated to their vested accounts or 50% of all of their Plan accounts up to \$50,000, subject to Puerto Rico Internal Revenue Code limitations and restrictions. Participants pay interest on such borrowings at the prime rate in effect at the time the participant loan is made. Loans must be repaid within five years (or by the employee's anticipated retirement date, if sooner) unless the loan is used for the purchase of the primary residence of the employee, in which case the repayment period can be extended to a period of fifteen years (or until the employee's anticipated retirement date, if sooner). Repayment is generally made through periodic payroll deductions or by sending in a payment, but a loan may be repaid in a lump sum at any time. Post-termination loan repayments are permitted. For employees whose account is distributed during the repayment period, the balance of the outstanding loan is netted from their Plan distribution.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Accounting

The financial statements have been prepared using the accrual basis of accounting.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and changes therein, and disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

Investment Valuation

The Plan uses the following methods and significant assumptions to estimate the fair value of investments:

Common stock and mutual funds - Valued at the published market price per share or unit multiplied by the number of shares or units held.

Collective trust funds and Private 40-Act mutual funds - Valued at the net asset value ("NAV") provided by the administrator of the fund. The NAV is used as a practical expedient to estimate fair value. The NAV is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding.

The following tables summarize the basis used to measure investments at fair value at December 31, 2023 and 2022 (dollars in thousands):

	Basis of Fair Value Measurement				Total
	Quoted Prices in Active Markets	Significant Other Observable Inputs	Significant Unobservable Inputs	Measured at NAV	
2023					
Common stock	\$ 95,946	\$ -	\$ -	\$ -	\$ 95,946
Mutual funds	42,917	-	-	-	42,917
Collective trust funds	-	-	-	76,813	76,813
Private 40-Act mutual funds	-	-	-	1,983	1,983
Total investments at fair value	<u>\$ 138,863</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 78,796</u>	<u>\$ 217,659</u>

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

2022	Basis of Fair Value Measurement				Total
	Quoted Prices in Active Markets	Significant Other Observable Inputs	Significant Unobservable Inputs	Measured at NAV	
Common stock	\$ 99,063	\$ -	\$ -	\$ -	\$ 99,063
Mutual funds	36,775	-	-	-	36,775
Collective trust funds	-	-	-	68,355	68,355
Total investments at fair value	<u>\$ 135,838</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 68,355</u>	<u>\$ 204,193</u>

Participants are permitted to make redemptions from the Plan's investment options on a daily basis, however, certain investments valued at NAV as a practical expedient have redemption requirements and in some cases restrictions for a Plan level redemption. The following tables provide the redemption requirements and restrictions, if any, for those investments as of December 31, 2023 and 2022. In addition, the tables provide the investment strategies for certain investments measured at NAV as a practical expedient, if that investment is a fund that does not file an annual report on Form 5500 as a direct-filing entity.

	2023			Restrictions
	Fair value (NAV)	Redemption frequency	Redemption notice period	
Funds filing as direct filing entity:				
Collective trusts	\$ 76,813	Daily	0 - 5 days	--
Funds not filing as direct filing entity:				
Private 40-Act mutual funds				
Asset-backed securities	293	Daily	--	Yes (a)
Corporate fixed income	556	Daily	--	Yes (a)
Inflation-indexed bonds	80	Daily	--	Yes (a)
International fixed income	227	Daily	--	Yes (a)
Mortgage-related securities	301	Daily	--	Yes (a)
Municipal fixed income	25	Daily	--	Yes (a)
Short-term fixed income	96	Daily	--	Yes (a)
U.S. Government securities	405	Daily	--	Yes (a)
	1,983			
	<u>\$ 78,796</u>			

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE B - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Continued

Investment Valuation - Continued

	2022			
	Fair value (NAV)	Redemption frequency	Redemption notice period	Restrictions
Funds filing as direct filing entity:				
Collective trusts	\$ 68,355	Daily	0 - 5 days	--

- (a) The Private 40-Act mutual funds agree to redeem shares solely in cash up to the lesser of \$250,000 or 1% of the respective fund's net assets during any 90-day period for any one shareholder. In consideration of the best interests of the remaining shareholders, the Private 40-Act mutual funds reserve the right to pay any redemption proceeds exceeding this amount in whole or in part by a distribution in kind of securities held by the respective fund in lieu of cash. It is highly unlikely that shares would ever be redeemed in kind. Redemption proceeds are ordinarily wired within three business after receipt of the redemption request, but may take up to seven days.

Notes Receivable from Participants

Notes receivable from participants are measured at their unpaid balance plus any accrued but unpaid interest. Delinquent loans are reclassified as distributions based upon the terms of the Plan.

Income Recognition

Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date. Net realized and unrealized appreciation/depreciation is recorded in the accompanying statement of changes in net assets available for benefits as net appreciation in fair value of investments.

Administrative Expenses

Participants are charged transaction fees for loan processing and commissions on purchases and sales of Abbott shares and sales of AbbVie shares. Investment fees for mutual funds and collective trusts are charged against the net assets of the respective fund. The Company pays other record-keeping and administration fees, where applicable.

Payment of Benefits

Benefits are recorded when paid.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE C - INVESTMENTS

Distributions of Abbott common shares and conversions of participants' common share account balances to participant loans or other investment options are recorded at fair market value.

A summary of Abbott common share data as of December 31, 2023 and 2022 is presented below:

	2023	2022
Abbott common shares, 581,107 and 587,473 shares, respectively (dollars in thousands)	\$ 63,962	\$ 64,499
Market value per share	\$ 110.07	\$ 109.79

NOTE D - RELATED-PARTY AND PARTY-IN-INTEREST TRANSACTIONS

The Plan holds units of collective trust funds managed by the Custodian. A significant portion of the Plan's assets is invested in Abbott common shares. These transactions qualify as party-in-interest transactions; however, they are exempt from the prohibited transaction rules under ERISA. During 2023, the Plan received \$1,194,000 in common stock dividends from Abbott.

Participants pay fees to the recordkeeper for loan transaction processing and for commissions on purchases and sales of Abbott shares and sales of AbbVie stock. These transactions qualify as permitted party-in-interest transactions.

NOTE E - PLAN TERMINATION

The Plan may be terminated at any time by Abbott upon written notice to the Trustee and Committee. All participants' account balances would become fully vested upon Plan termination. Upon termination of the Plan, distributions of each participant's share in the trust, as determined by the terms of the Plan, would be made to each participant. At the present time, Abbott has no intention of terminating the Plan.

Abbott Laboratories Stock Retirement Plan (Puerto Rico)
NOTES TO FINANCIAL STATEMENTS - CONTINUED
December 31, 2023 and 2022

NOTE F - TAX STATUS

The Plan received letters dated April 19, 2016 and December 2, 2019 from the Department of the Treasury of the Commonwealth of Puerto Rico that the Plan, as written, qualifies under Section 1081.01(a) of the Puerto Rico Internal Revenue Code of 2011, as amended and, consequently, its enabling trust is exempt from local income tax. The Plan has been amended since receiving the letters. The Plan administrator believes that the Plan is designed and is currently being operated, in all material respects, in accordance with the applicable Puerto Rico Internal Revenue Code.

Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the applicable taxing authorities. The Plan administrator has analyzed the tax positions taken by the Plan, and has concluded that as of December 31, 2023 and 2022, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress.

NOTE G - RISKS AND UNCERTAINTIES

In general, the investments provided by the Plan are exposed to various risks, such as interest rate, credit and overall market volatility risks. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participant accounts and the amounts reported in the statements of net assets available for benefits.

NOTE H - SUBSEQUENT EVENTS

Management of the Plan has evaluated subsequent events from December 31, 2023 through the date these financial statements were issued. Management of the Plan is not aware of any subsequent events that require recognition or additional disclosure in these financial statements.

SUPPLEMENTAL SCHEDULE

Abbott Laboratories Stock Retirement Plan (Puerto Rico)**EIN: 98-1051267, Plan Number: 002****SCHEDULE H, LINE 4i - SCHEDULE OF ASSETS (HELD AT END OF YEAR)****December 31, 2023****(Dollars in thousands)**

		(c) Description of investment including maturity date & range of interest	(d) Cost **	(e) Current value
(a)	(b) Identity of issue, borrower, lessor, or similar party			
	Common stock - employer securities			
*	Abbott Laboratories, common shares			\$ 63,962
	Common stock			
	AbbVie Inc., common stock			31,984
	Total Common stock			95,946
	Mutual funds			
	American Funds EuroPacific Growth Fund			5,582
	American Funds The Growth Fund of America Fund			16,152
	American Funds Washington Mutual Investors Fund			3,870
	PIMCO All Asset Fund			2,767
	PIMCO Short Asset Investment Fund			11,029
	Vanguard Mid-Cap Value Index Fund Admiral			3,517
	Total Mutual funds			42,917
	Collective trust funds			
	Blackrock International Opportunities Fund			1,994
	GW&K Small-Mid Cap Core Equity Fund			3,154
*	Northern Trust Collective ACWI ex-U.S. Index Fund			801
*	Northern Trust Collective Short Term Investment Fund			294
	SSGA Russell Small/Mid Cap Index Fund			3,919
	SSGA S&P 500 Index Fund			16,394
	SSGA U.S. Bond Index Fund			754
	SSGA Target Retirement 2020			4,181
	SSGA Target Retirement 2025			7,505
	SSGA Target Retirement 2030			10,330
	SSGA Target Retirement 2035			6,572
	SSGA Target Retirement 2040			6,276
	SSGA Target Retirement 2045			4,954
	SSGA Target Retirement 2050			2,863
	SSGA Target Retirement 2055			1,731
	SSGA Target Retirement 2060			536
	SSGA Target Retirement 2065			208
	SSGA Target Retirement Income			4,347

Total Collective trust funds		<u>76,813</u>
Private 40-Act mutual funds		
PIMCO Asset-Backed Securities Portfolio		293
PIMCO Emerging Markets Portfolio		93
PIMCO High Yield Portfolio		23
PIMCO International Portfolio		134
PIMCO Investment Grade Credit Bond Portfolio		533
PIMCO Mortgage Portfolio		301
PIMCO Municipal Sector Portfolio		25
PIMCO Real Return Portfolio		80
PIMCO Short-Term Floating NAV Portfolio II		96
PIMCO U.S. Government Sector Portfolio		<u>405</u>
Total Private 40-Act mutual funds		1,983
Interest rates 3.25% to 8.50%		
Maturing 2024 through 2038		
* Loans to participants		<u>5,172</u>
		<u><u>\$ 222,831</u></u>

* Represents a party-in-interest transaction.

** Cost information omitted as all investments are fully participant directed.

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Exhibit</u>
<u>23.1</u>	<u>Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan.</u>
<u>23.2</u>	<u>Consent of Independent Registered Public Accounting Firm – Abbott Laboratories Stock Retirement Plan (Puerto Rico).</u>

SIGNATURE

The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

ABBOTT LABORATORIES STOCK RETIREMENT PROGRAM

Date: June 25, 2024

By: /s/ Sean J. Treacy
Sean J. Treacy
Plan Administrator

|

|